Oasmia Competitors

Delisted . USA . 
Stock . Oasmia Pharmaceutical AB
OASMYDelisted Stock  USD 0.06  0.00  0.00%   
Oasmia Pharmaceutical competes with Ryanair Holdings, LENSAR, Cumberland Pharmaceuticals, Finnair Oyj, and Alaska Air; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Oasmia Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Oasmia Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Oasmia Pharmaceutical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.060.060.06
Details
Intrinsic
Valuation
LowRealHigh
0.060.060.06
Details

Oasmia Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Oasmia Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Oasmia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Oasmia Pharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ALK
+ 0.85
LNSR
GFF
+ 0.63
LNSR
GFF
+ 0.6
ALK
ALK
+ 0.48
RYAAY
FNNNF
+ 0.3
CPIX
LNSR
+ 0.26
RYAAY
  
High negative correlations   
ALK
- 0.87
CPIX
GFF
- 0.74
FNNNF
CPIX
- 0.7
LNSR
GFF
- 0.59
CPIX
FNNNF
- 0.52
LNSR
CPIX
- 0.45
RYAAY

Risk-Adjusted Indicators

There is a big difference between Oasmia Pink Sheet performing well and Oasmia Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oasmia Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Oasmia Pharmaceutical Competitive Analysis

The better you understand Oasmia Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Oasmia Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Oasmia Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
OASMY RYAAY LNSR CPIX FNNNF ALK GFF
 0.00 
 0.06 
Oasmia
 1.07 
 43.32 
Ryanair
 1.09 
 7.44 
LENSAR
 4.72 
 1.11 
Cumberland
 0.85 
 2.33 
Finnair
 0.95 
 52.93 
Alaska
 0.93 
 84.37 
Griffon
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Moderately volatile
Moderately volatile
Relatively risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Weak
Good
Very Weak
Very Weak
Solid
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Low
Below Average
Below Average
Low
Very Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Hold
Cautious Hold
Strong Sell
Strong Buy
Buy
Current Ratio
6.80 X
1.08 X
3.14 X
1.80 X
1.03 X
0.81 X
2.26 X
Net Asset
594.31 M
17.18 B
69.58 M
81.78 M
4.05 B
15.83 B
2.37 B
Profit Margin
N/A
0.11 %
(0.34) %
(0.30) %
(0.29) %
0.03 %
0.08 %
EBITDA
(97.54 M)
3.06 B
(8.71 M)
(710.85 K)
(173.7 M)
1.27 B
461.44 M
Current Valuation
6.58 M
20.12 B
69.53 M
18.9 M
1.93 B
10.42 B
5.56 B
Price To Book
0.68 X
2.93 X
3.77 X
0.60 X
1.57 X
1.49 X
17.64 X
Operating Margin
N/A
0.33 %
(0.09) %
(0.19) %
(0.14) %
0.13 %
0.20 %
Retained Earnings
N/A
5.9 B
(111.89 M)
(17.49 M)
302 M
4.54 B
461.44 M
Current Asset
N/A
4.82 B
N/A
66.96 M
1.34 B
1.66 B
382.34 M
Five Year Return
N/A
N/A
N/A
N/A
N/A
1.95 %
1.48 %
Beta
0.0522
1.39
0.59
0.22
1.47
1.59
1.27
Number Of Employees
17
27 K
130
91
5.33 K
23.78 K
N/A
Shares Outstanding
179.35 M
543.12 M
11.61 M
14.04 M
1.41 B
126.94 M
47.82 M
Cash Flow From Operations
(145.56 M)
3.16 B
(9.66 M)
6.09 M
(25.3 M)
1.05 B
380.04 M
Annual Yield
0.12 %
0.02 %
N/A
N/A
N/A
N/A
0.01 %
Total Debt
N/A
2.75 B
2.31 M
18.43 M
986.2 M
3.82 B
1.71 B
Return On Equity
-0.25
0.19
-0.38
-0.36
-1.35
0.0751
0.78
Return On Asset
-0.0875
0.0634
-0.0938
-0.0564
-0.0433
0.0286
0.12
Number Of Shares Shorted
20.72 K
7.81 M
49.75 K
76.74 K
N/A
8.87 M
2.67 M
Book Value Per Share
N/A
7.09 X
1.96 X
1.77 X
0.25 X
35.51 X
4.83 X
Current Liabilities
N/A
3.37 B
N/A
11.69 M
925 M
1.8 B
189.15 M
Total Asset
594.31 M
17.18 B
69.58 M
81.78 M
4.05 B
15.83 B
2.37 B
Debt To Equity
0.01 %
0.81 %
0.07 %
0.50 %
9.04 %
1.03 %
1.97 %
Short Ratio
0.03 X
5.46 X
1.54 X
2.31 X
N/A
3.94 X
7.89 X
Target Price
6.0
53.0
11.0
8.5
N/A
60.34
101.0
Last Dividend Paid
N/A
0.58
N/A
N/A
N/A
N/A
0.6
Shares Owned By Institutions
N/A
45.89 %
42.43 %
14.68 %
9.51 %
88.10 %
77.72 %
Market Capitalization
21.21 M
23.78 B
85.48 M
14.88 M
773.85 M
6.78 B
4.07 B
Price To Earning
N/A
16.27 X
N/A
(16.05) X
8.43 X
112.95 X
19.62 X
Price To Earnings To Growth
N/A
3.63 X
N/A
N/A
N/A
1.30 X
2.36 X
Price To Sales
31.16 X
1.75 X
1.75 X
0.40 X
0.35 X
0.63 X
1.55 X
Net Income
(132.72 M)
1.92 B
(14.38 M)
(6.28 M)
(464.3 M)
235 M
209.9 M
Earnings Per Share
N/A
1.85 X
(1.46) X
(0.76) X
(0.40) X
2.51 X
4.23 X
Shares Owned By Insiders
N/A
N/A
19.57 %
44.72 %
56.50 %
0.45 %
18.48 %
Revenue
26.19 M
13.44 B
42.16 M
39.55 M
838.4 M
10.43 B
2.62 B
Working Capital
N/A
(573.5 M)
34.81 M
7.73 M
414 M
(1.47 B)
580.49 M
Cash And Equivalents
N/A
4.62 B
25.2 M
18.22 M
1.64 B
338 M
120.18 M
Cash Per Share
N/A
20.37 X
2.29 X
1.24 X
1.17 X
24.83 X
2.81 X
Gross Profit
(15.25 M)
791.1 M
19.95 M
32.89 M
(158.9 M)
2.36 B
1.03 B
Day Typical Price
0.06
43.21
7.54
1.1
2.33
53.33
84.31
Accumulation Distribution
N/A
27549.28
3242.05
1239.38
N/A
26016.73
10343.47
Daily Balance Of Power
0.0
(0.49)
0.1333
0.8333
(9,223,372,036,855)
(0.41)
(0.63)
Period Momentum Indicator
N/A
(0.47)
0.08
0.05
(0.02)
(0.51)
(0.79)
Rate Of Daily Change
1.0
0.99
1.01
1.05
0.99
0.99
0.99
Day Median Price
0.06
43.16
7.59
1.09
2.33
53.53
84.28
Price Action Indicator
N/A
(0.07)
(0.11)
0.045
(0.01)
(0.85)
(0.30)
Coefficient Of Variation
(3,398)
1892.8
617.07
(605.70)
(2,547)
324.71
717.83
Mean Deviation
5.8
1.55
3.38
1.79
0.4666
1.55
1.73
Jensen Alpha
(0.07)
0.0392
0.7333
(0.42)
(0.06)
0.4944
0.1997
Total Risk Alpha
(4.08)
(0.22)
0.0234
(0.75)
(0.38)
0.3038
(0.06)
Sortino Ratio
N/A
(0.01)
0.147
N/A
N/A
0.3249
0.1379
Downside Variance
N/A
4.27
20.32
N/A
N/A
2.41
4.13
Standard Deviation
22.02
2.01
4.88
2.32
1.9
2.05
2.94
Kurtosis
30.04
0.2596
3.29
0.066
41.77
0.71
20.34
Potential Upside
N/A
3.77
8.92
3.51
N/A
4.71
3.15
Treynor Ratio
0.1324
0.2005
1.93
(1.51)
0.4545
0.5754
0.2375
Maximum Drawdown
190.0
8.74
22.69
10.64
19.58
9.94
22.83
Variance
484.82
4.02
23.84
5.38
3.61
4.22
8.62
Market Risk Adjusted Performance
0.1424
0.2105
1.94
(1.50)
0.4645
0.5854
0.2475
Risk Adjusted Performance
(0.01)
0.0466
0.1323
(0.12)
(0.02)
0.2416
0.1139
Skewness
3.63
0.043
0.3754
(0.17)
(5.13)
0.6024
3.32
Semi Deviation
N/A
1.94
3.84
N/A
N/A
0.9455
1.73
Information Ratio
(0.04)
(0.01)
0.1357
(0.22)
(0.11)
0.2454
0.0955
Value At Risk
(16.67)
(3.25)
(5.53)
(4.69)
N/A
(2.09)
(3.12)
Expected Short fall
N/A
(1.52)
(3.85)
N/A
N/A
(1.86)
(1.98)
Downside Deviation
N/A
2.07
4.51
N/A
N/A
1.55
2.03
Semi Variance
N/A
3.75
14.77
N/A
N/A
0.8939
3.0

Oasmia Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Oasmia Pharmaceutical Competition

Oasmia Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Oasmia Pharmaceutical in relation to its competition. Oasmia Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Oasmia Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Oasmia Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Oasmia Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Oasmia Pharmaceutical position

In addition to having Oasmia Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recycling Thematic Idea Now

Recycling
Recycling Theme
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Oasmia Pink Sheet

If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY